A number of injector pens for the Wegovy weight reduction drug are proven on this photograph illustration in Chicago, Illinois, March 31, 2023.
Jim Vondruska | Reuters
Wegovy, the favored weight reduction drug from Novo Nordisk, considerably decreased signs of a standard kind of coronary heart failure in sufferers with weight problems, in response to a late-stage scientific trial launched Friday.
Wegovy helped alleviate signs like shortness of breath, fatigue, swelling within the legs and irregular coronary heart beat. It additionally resulted in decrease blood stress and reductions in irritation – two vital markers of coronary heart well being.
The outcomes add to Wegovy’s rising checklist of potential well being advantages past shedding undesirable kilos. That would doubtlessly result in expanded use of the drug and elevated protection by insurers. The outcomes additionally complement the groundbreaking trial knowledge Novo Nordisk launched earlier this month, which discovered that Wegovy slashed the chance of great heart-related issues by 20%.
“We look ahead to working carefully with the scientific neighborhood and regulators to assist realise this potential over the approaching months,” Martin Lange, Novo Nordisk’s head of growth, stated in a launch. He was referring to the center well being advantages noticed in each trials.
The brand new research on 529 overweight sufferers centered on a coronary heart situation often known as preserved ejection fraction, or HFpEF – a situation that includes roughly half of all coronary heart failure circumstances within the U.S. and happens when the center’s decrease chamber pumps much less blood than the physique wants.
An estimated 2.5 million individuals within the U.S. have that situation and greater than 80% of these sufferers even have weight problems.
The research, printed within the New England Journal of Drugs, discovered that Wegovy led to an almost 17-point enchancment on a 100-point scale that is used to evaluate signs of HFpEF.
By comparability, sufferers who acquired a placebo had a 9-point enchancment.
Wegovy additionally led to enhancements in bodily limitations: Sufferers who took the drug had been capable of stroll additional in six minutes than these within the placebo group.
These on Wegovy additionally misplaced about 13% of their physique weight, in contrast with 2.6% for these on a placebo, over the course of the year-long trial.
There have been fewer severe security occasions in sufferers who took Wegovy in contrast with those that took the placebo. However extra sufferers stopped taking Wegovy due to gastrointestinal points, that are generally noticed with different weight reduction medication.
One limitation of the trial was its lack of range: 96% of the contributors had been white.
Wegovy and Novo Nordisk’s diabetes drug Ozempic sparked a weight reduction business gold rush final 12 months for serving to sufferers lose undesirable weight. They’re a part of a category of medication referred to as GLP-1 agonists, which mimic a hormone produced within the intestine to suppress an individual’s urge for food.
However Novo Nordisk is grappling with provide constraints which have led to shortages of each medication.
There are additionally current studies of sufferers who had suicidal and self-harm ideas after taking Wegovy and different weight reduction medication, which raised questions concerning the unintended and doubtlessly life-threatening uncomfortable side effects of the remedies
